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ABSTRACT
The TSANZ develops position statements where insuffi-
cient data exist to write formal clinical guidelines. In
2018, the TSANZ addressed the question of potential
benefits and health impacts of electronic cigarettes (EC).
The working party included groups focused on health
impacts, smoking cessation, youth issues and priority
populations. The 2018 report on the Public Health Con-
sequences of E-Cigarettes from the United States NASEM
was accepted as reflective of evidence to mid-2017.
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A search for papers subsequently published in peer-
reviewed journals was conducted in August 2018. A small
number of robust and important papers published until
March 2019 were also identified and included. Groups
identified studies that extended, modified or con-
tradicted the NASEM report. A total of 3793 papers were
identified and reviewed, with summaries and draft posi-
tion statements developed and presented to TSANZ
membership in April 2019. After feedback from members
and external reviewers, a collection of position state-
ments was finalized in December 2019. EC have adverse
lung effects and harmful effects of long-term use are
unknown. EC are unsuitable consumer products for rec-
reational use, part-substitution for smoking or long-term
exclusive use by former smokers. Smokers who require
support to quit smoking should be directed towards
approved medication in conjunction with behavioural
support as having the strongest evidence for efficacy and
safety. No specific EC product can be recommended as
effective and safe for smoking cessation. Smoking cessa-
tion claims in relation to EC should be assessed by
established regulators.
Key words: e-cigarettes, public health, smoking cessation,
tobacco control, vaping.
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INTRODUCTION
Electronic cigarettes (e-cigarettes) are battery-operated
devices which contain a heating element that vaporizes
liquid solution. The user inhales or ‘vapes’ the aerosol
produced through heating the liquid. E-cigarettes are also
referred to as electronic nicotine delivery systems (ENDS)
or electronic non-nicotine delivery systems (ENNDS)
when they do not use nicotine-based solutions.
The liquid solution used in e-cigarettes contains pro-
pylene glycol and/or glycerine liquid to create the aero-
sol.1 The solution often contains flavourants and ENDS
solutions contain nicotine.
Early attempts to develop e-cigarettes date to the 1960s,
but the first device of the modern era was patented in
2003. E-cigarettes have been widely marketed since about
2006. Use of an e-cigarette is commonly termed ‘vaping’.
Tobacco smoking in Australia and New
Zealand
The advent of e-cigarettes has occurred after sustained
success in reducing tobacco smoking rates in Australia
and New Zealand.
Australia has led the world in implementing tobacco
control measures including substantial increases in
excise on tobacco products; education programmes;
bans on smoking in indoor and, increasingly, outdoor
public places; plain packaging of tobacco products;
bans on retail displays of tobacco products; labelling
with updated and larger graphic health warnings;
prohibiting tobacco advertising, promotion and spon-
sorship; and providing support for smokers to quit
including subsidized nicotine replacement therapy.2–5
The rates of regular smoking in Australia (that is either
daily or at least weekly) have reduced from 27% in
1995 to 14% in 2016.6
Smoking rates in New Zealand Aotearoa are also
reducing, with 12.5% of adults currently smoking daily
compared to 25% in 1996–1997.7 In 2011, the New
Zealand Government set a goal of Smokefree Aotearoa
2025, aiming to reduce smoking prevalence and
tobacco availability to minimal levels and make New
Zealand essentially a smoke-free nation by 2025.8 Strat-
egies have included protecting children from exposure
to tobacco marketing and promotion; reducing the
supply of, and demand for, tobacco; and providing the
best possible support for quitting.
Smoking by young people has fallen markedly.
Smoking rates among young Australians aged 16–
17 years declined from 30% in 1999 to 10% in 2014,
while among those aged 12–15 years, the smoking rate
declined from 15% to 3% during the same period.9 The
prevalence of smoking among Australian teenagers in
2014 was at its lowest since surveys began more than
30 years earlier. Similar improvements have been
achieved in New Zealand, where only 3% of young peo-
ple aged 15–17 years smoked in 2017–2018, down from
16% in 2006–2007 and the daily smoking rate for 14-
and 15-year olds fell to 2.1%, the lowest ever recorded.7
Harmful effects of smoking
There is no dispute about the harmful effects and sig-
nificant costs of tobacco smoking. Smoking causes the
premature deaths of two-thirds of its long-term users.10
Respiratory diseases, notably lung cancer and chronic
obstructive pulmonary disease (COPD), dominate as
causes of smoking-associated disability and premature
mortality in both Australia and New Zealand.
In 2015–2016, the costs of smoking in Australia were
estimated at $136.9 billion and smoking was responsi-
ble for 20 032 premature deaths and approximately 1.7
million hospitalizations.11 In New Zealand, approxi-
mately one person dies from smoking every 2 hours,
while in Australia approximately one person dies from
smoking every half an hour.12,13
These harmful effects continue to occur despite the sig-
nificant success in reducing rates of tobacco smoking in
Australia and New Zealand, and it is imperative this pro-
gress continues. In recent years, the emergence of e-ciga-
rettes has prompted discussion about whether these
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devices have a role in supporting smokers to quit or in
reducing smoking prevalence rates.
Purpose of this position paper
The Thoracic Society of Australia and New Zealand
(TSANZ) position papers reflect the position of the
TSANZ where there are insufficient data to support a
formal clinical guideline (particularly in areas of public
health policy). In contrast to position papers, the
TSANZ’s guidelines must provide evidence-based rec-
ommendations for clinical practice, require a system-
atic review of the literature and use GRADE levels of
evidence.
The TSANZ determined that a position paper was
required on e-cigarettes, given the rapidly emerging
research in this area, the recognition that the health
effects of e-cigarettes are likely to only become fully
understood over time and the scant evidence for their
use in smoking cessation. This position paper was
completed in accordance with the TSANZ requirements
for the development of position papers as detailed in
the TSANZ publication policy.
The TSANZ is dedicated to ensuring that Australian
and New Zealand governments maintain their commit-
ment to reducing smoking prevalence and to the imple-
mentation of comprehensive tobacco control measures
that include population-wide strategies coupled with
individual behavioural support, particularly for groups
of people in whom smoking rates have not declined as
quickly as they have in others. The TSANZ is committed
to preventing and relieving the disability caused by lung
disease. Consequently, we are steadfast in our aim to
help people stop smoking completely. E-cigarettes are
therefore of considerable interest to the TSANZ as we
seek to further reduce the morbidity and mortality asso-
ciated with lung disease. The purpose of this position
paper is to outline the TSANZ’s position with respect to
e-cigarettes. The intended audience is both clinical and
non-clinical readers.
This position paper addresses e-cigarettes that use
both nicotine-containing and non-nicotine-containing
liquids but does not consider ‘heat-not-burn’ products,
a separate product category.
The TSANZ acknowledges the Public Health England
Report on e-cigarettes.14 The TSANZ has considered
and accepted the comprehensive report on the Public
Health Consequences of E-Cigarettes from the United
States National Academies of Sciences, Engineering
and Medicine (NASEM), January 2018,15 as well as the
June 2018 Literature Review Update from Australia’s
Commonwealth Scientific and Industrial Research
Organisation (CSIRO)16 as better reflecting the publi-
shed literature to August 2017 and March 2018, respec-
tively. As such, these reports form the basis for the
development of the TSANZ’s position.
In developing this position paper, we reviewed the
literature to determine if there were new studies that
subsequently extended or challenged the findings of
the NASEM report. In particular, we reviewed literature
predominantly, but not exclusively, post-dating August
2017, that assessed e-cigarettes with respect to:
1. Health impacts,
2. Effects on smoking cessation,
3. Effects on children and young people including the
impact of both nicotine- and non-nicotine-con-
taining products on developing lungs and
4. Effects on at-risk groups which included:
• Aboriginal, Torres Strait Islanders, Maori, Pasifika
peoples,
• Prisoners (or those recently released),
• People with mental illness,
• Alcohol and other drug treatment clients and
• Pregnant women.
Working party membership is listed in Supplemen-
tary Appendix S1 and Methodology is outlined in Sup-
plementary Appendix S2.
THE REGULATORY FRAMEWORK
In Australia, the regulation of e-cigarettes is a responsi-
bility shared between Commonwealth and State and
Territory Governments across multiple sets of legisla-
tion relating to tobacco products, therapeutic goods,
poisons and consumer goods. The regulatory frame-
works are different in each state and territory. Whereas
in New Zealand nicotine-containing e-cigarettes are
available as a consumer product, this is not the case in
Australia, where e-cigarettes can be purchased as a
consumer product, but nicotine cannot. In New
Zealand, the Medicines Act 1981 and the Smoke-Free
Environments Act 1990 regulate the sale, advertising
and use of vaping products, including nicotine liquids.
It is illegal in both New Zealand and Australia to sell
an e-cigarette while making a claim about therapeutic
benefit for smoking cessation unless the product has
been approved for that purpose by the Therapeutic
Goods Administration (Australia) or Medsafe (New
Zealand). In both Australia and New Zealand, e-ciga-
rettes are currently sold as consumer products and not
as therapeutic goods.
Smoking cessation products have been subject to
stringent regulation through government-managed
processes. Regulated therapeutic goods are man-
ufactured under strict codes such as Good Manufactur-
ing Practice to ensure product consistency and quality.
E-cigarettes are not regulated as a therapeutic product.
Regulation is the role of government. The Institute
for Global Tobacco Control website (https://
globaltobaccocontrol.org/e-cigarette_policyscan) pro-
vides a detailed overview of how governments interna-
tionally have approached the regulation of e-
cigarettes.17 There is no current evidence on the most
effective regulatory framework for e-cigarettes.
HEALTH IMPACTS OF E-CIGARETTES
Drawing conclusions about absolute exposure levels
and associated risk based on comparisons between e-
cigarettes and combustible tobacco use is not possible.
There are thousands of e-liquid solution variants and a
range of devices with different settings. Exposure to
certain toxins in e-cigarettes has been demonstrated to
be less than that experienced with conventional ciga-
rette use, whilst for others exposure is greater.15
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Although the NASEM report concluded that there
was no available evidence regarding whether e-ciga-
rettes cause respiratory diseases in humans, we identi-
fied two subsequently published studies which
compared the spectrum of bronchial proteins in non-
smokers, smokers and e-cigarette users. They demon-
strated alterations in the bronchial proteome and iden-
tified changes unique to e-cigarettes, including markers
of an aberrant neutrophilic response.18,19 In vivo stud-
ies have identified specific e-cigarette flavourants that
have potential adverse effects on human health,20,21
and a study in humans showed addition of a flavourant
led to increased plasma nicotine levels.22
A recent prospective cohort study, based on a large
sample of current or former smokers, found that e-cig-
arettes used alone or in combination with tobacco ciga-
rettes, compared to smoking tobacco cigarettes alone
did not substantially improve self-reported health over
4 years of follow-up or decrease the rate of diseases
potentially related to tobacco.23 Nonetheless, the
authors acknowledged that the follow-up period may
have been too short to detect long-term effects.
The NASEM report concluded that the implications
for long-term effects on morbidity and mortality are
not yet clear and noted substantial evidence that e-cig-
arette aerosol induces cellular dysfunction and can
promote the formation of reactive oxygen species/oxi-
dative stress. It also noted, however, that the genera-
tion of reactive oxygen species and oxidative stress is
generally lower from e-cigarettes than from combusti-
ble tobacco smoke.15 The studies identified above fur-
ther support the NASEM assessment that lung disease
is a biologically plausible potential outcome of long-
term exposure to e-cigarette vapour.
Continued smoking is seen in the majority of e-ciga-
rette users.24 There is sparse evidence in humans of
the health outcomes in these dual users of e-cigarettes
and tobacco. The NASEM report noted a lack of clarity
regarding the balance of positive and negative effects of
e-cigarettes on respiratory health, concluding that there
is limited evidence for improvement in lung function
and respiratory symptoms among adult smokers with
asthma who switch to e-cigarettes completely or in part
(dual use) and for reduction of COPD exacerbations
among adult smokers with COPD who switch to e-ciga-
rettes completely or in part.
Isolated case studies and case series have described
adverse effects of e-cigarettes on a range of non-respi-
ratory outcomes including accidental poisoning from
e-liquids,25 acute nicotine toxicity from excessive
vaping26 and increased periodontal inflammation.27
During the process of finalization of this document,
a substantial number of cases of severe, acute lung
injury in e-cigarette users have been reported in the
United States. A summary of this outbreak is provided
in Appendix S3 (Supplementary Information).
Non-respiratory adverse effects of e-cigarettes from
malfunction of the devices have been identified,
including lacerations and burns that have resulted from
explosions.28–30
There is little evidence about the effects of e-ciga-
rette use on pregnancy and foetal health.
Research on the effects of second-hand exposure to
e-cigarette aerosols has been challenged by difficulty in
creating an effective model of exposure—due to a
range of factors including heterogeneity of apparatus
and juices, adjustable power settings and varying puff
parameters.
The long-term health impact of e-cigarettes remains
largely unknown. Given the known short- to mid-term
adverse health effects and the risk that chronic lung
disease will develop over time, e-cigarettes should not
be used by children or non-smokers. Their use by
smokers is addressed in the following section on
smoking cessation.
EFFECTS ON SMOKING CESSATION
The NASEM15 and CSIRO16 reports, together with
reports from Australia’s National Health and Medical
Research Council31 and a European Respiratory Society
Task Force,32 all conclude that there is limited evidence
that e-cigarettes are effective in promoting smoking
cessation and a lack of evidence as to whether e-ciga-
rettes are more or less effective than existing approved
cessation aids or no treatment.
A literature search identified five additional random-
ized controlled trials relevant to smoking cessation
published since the finalization of the 2018 NASEM
report. The trials were heterogeneous in study popula-
tion and design. In two studies of smokers motivated to
quit, one showed an increase in stopping rates with e-
cigarettes, with or without nicotine, compared to low-
intensity counselling,33 but the other found no incre-
mental effect when e-cigarettes were added to com-
bined nicotine replacement therapy and counselling.34
Three studies investigated smokers not motivated to
quit. They found that the addition of free e-cigarettes
to usual care (information and motivational text mes-
sages) did not increase sustained smoking absti-
nence;35 provision of free e-cigarettes for use entirely at
the discretion of participants did not significantly influ-
ence quit attempts or biologically verified abstinence;36
and randomization to ad libitum nicotine-containing
rather than non-nicotine-containing e-cigarettes did
not reduce regular cigarette use.37
A recent randomized trial investigated the efficacy of e-
cigarettes compared with nicotine replacement therapy,
in addition to face-to-face cessation counselling, in
smokers attending a smoking cessation service.38 At
1 year, the rate of continuous abstinence from smoking
traditional cigarettes among e-cigarette users was 18.0%
compared to 9.9% in the nicotine replacement group (rel-
ative risk: 1.83; 95% CI: 1.30–2.58; P < 0.001). However,
after 1 year, 80% of e-cigarette users continued to use e-
cigarettes, whereas 9% of nicotine replacement therapy
users were still using nicotine replacement.
A time series analysis in the United Kingdom found no
significant association between changes in the use of e-
cigarettes between 2006 and 2016 and rates of smoking
and daily cigarette consumption.39 It concluded that if e-
cigarette use had any effect on cigarette smoking, the
effect was likely to be very small at a population level.
Most smokers quit smoking unassisted,40 but effec-
tive healthcare advice and the appropriate use of
proven and well-regulated products are essential in
providing support for many smokers seeking assistance
© 2020 The Authors.
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in quitting. Guidelines are available for health profes-
sionals to assist them in providing expert care.41,42 If
health practitioners are unable to support smokers,
they should refer them to appropriate expert care.
Smokers seeking to quit require access to qualified,
personal behavioural support regardless of whether
they use existing therapies. Smokers who enquire
about using e-cigarettes as a cessation aid should be
provided with appropriate information about approved
medication in conjunction with behavioural support
(as these have the strongest evidence of efficacy to
date). E-cigarettes are not the first-line treatment for
smoking cessation.41 However, for smokers who
express a desire to use e-cigarettes for cessation, health
professionals should ensure they have access to, and
are utilizing, behavioural support with the aim of
achieving complete smoking cessation and subsequent
cessation of e-cigarette use as promptly as possible.
IMPLICATIONS FOR CHILDREN AND
YOUNG PEOPLE
The NASEM report found substantial evidence that e-
cigarette use results in young people taking up smoking
of conventional cigarettes (the gateway effect).15 The
reports from the CSIRO,16 NHMRC31 and European
Respiratory Society Task Force32 agreed. The Forum of
International Respiratory Societies recommends that,
to protect youth, e-cigarettes should be considered as
tobacco products and regulated as such.43 The addic-
tive power of nicotine, particularly in the developing
adolescent brain, and its adverse effects should not be
underestimated. The Forum stated that flavourings fur-
ther encourage use by young people.
The United States Surgeon General concluded that e-
cigarette use among youth and young adults is a public
health concern.44 In 2014, use of e-cigarettes by young
adults aged 18–24 years in the United States exceeded
that of adults aged 25 years or over. The Surgeon General
concluded that e-cigarette use is strongly associated with
the use of other tobacco products among youth and
young adults, including combustible tobacco products.
One hundred and ninety-four papers concerning the
implications of e-cigarettes for children and young peo-
ple published since the NASEM report were consistent
with the NASEM findings. Many provided additional
supportive data. Seven reports challenged the cautionary
approach recommended by the NASEM analysis.45–51
IMPLICATIONS FOR AT-RISK GROUPS
Smoking rates are higher than average in some popula-
tion groups including Aboriginal and Torres Strait
Islander and Maori and Pasifika peoples. Smoking rates
are also elevated in people with mental illness or sub-
stance-use disorder and people in correctional facili-
ties. Women who are pregnant, or are planning to
become pregnant, have special health needs relating to
smoking.
We considered any studies published after the
NASEM report reporting on the groups identified above
in which e-cigarettes were considered as a cessation
aid, attitudes towards e-cigarettes were examined or
the level of use was assessed. We conclude that, due to
the low quality of evidence, it is uncertain whether e-
cigarettes are effective for smoking cessation in
populations with high smoking rates.52 Individual stud-
ies, reported both before and since the NASEM review,
varying in sample size from 12 to 84 participants
showed some sustained reduction in the number of
cigarettes smoked at 1 year (similar to the efficacy to a
nicotine replacement patch),53,54 reduced tobacco use
at 9 weeks,55 acceptability as a form of nicotine
replacement therapy in alcohol-dependent patients
during a hospital admission,56 acceptability and some
efficacy in military veterans receiving psychiatric ser-
vices57 and reduced smoking rates at 6 weeks in people
with severe mental illness.58
A 2015 review on behalf of the United States Preven-
tive Services Task Force examined e-cigarette use in all
adults.59 It identified no specific studies on the impact
on smoking cessation in pregnant women and stated
that the effects of e-cigarette ingredients on the foetus
are unknown. Five studies published since this review
examined attitudes to e-cigarette use in groups that
included pregnant women, people with mental illness
and Maori and Pasifika people in New Zealand.60–64
They identified positive views about e-cigarettes. Par-
ticipants considered them safer than tobacco products.
The prevalence of e-cigarette use in at-risk populations
has been assessed in a number of studies. It was esti-
mated that 11–13% of pregnant women in the United
States had prior or current use and 0.6% currently used
them daily.65 In American patients hospitalized for men-
tal illness, the prevalence of e-cigarette use increased
from zero in 2009 to 25% in 2013.66 A survey of 6051
Americans found people with mental illness were 1.5
times more likely to have ever used e-cigarettes and
almost twice as likely to be current users compared to
people without mental illness.67 Among Americans with
drug- and alcohol-use disorders, two studies showed 30–
34% had used e-cigarettes in the last 30 days,68,69 while
another found that 17.7% used them at least weekly.70
A study of 390 Indigenous Australians, of whom 184
were current smokers and 75 former smokers, found
that only 7 (2%) were currently using e-cigarettes.71 In
a 2013–2014 survey, 21% of Indigenous smokers had
tried an e-cigarette, virtually identical to the rate of
20% in all Australian smokers.5
The literature and evidence base for cessation,
acceptability and prevalence for each population were
sparse and the quality of the studies was not suffi-
ciently robust to enable conclusions to be drawn. Given
the burden of smoking in these populations, further
high-quality research utilizing e-cigarettes and existing
cessation aids is urgently required.
POSITION OF THE TSANZ
The TSANZ embarked upon the development of this
position paper having accepted the NASEM report as
the most comprehensive review on e-cigarettes to date.
After reviewing recent literature on e-cigarettes, it is
the position of the TSANZ that there is, at present,
insufficient evidence to refute the findings of the
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NASEM report. We believe that this position statement
is also fully consistent with relevant sections of the
2020 report of the US Surgeon General on Smoking
Cessation.24
The TSANZ, with its particular concern with respira-
tory health, has taken the position that:
1. All smokers should be able to easily access effec-
tive, existing cessation treatments complemented
by behavioural support services.
2. Access to effective, adequately funded smoking
cessation support services is particularly important
for those smokers in population groups where the
prevalence rates have remained high.
3. Smokers who enquire about using e-cigarettes as a
cessation aid should be provided with appropriate
information about approved medication in con-
junction with behavioural support (as these have
the strongest evidence for efficacy and safety).
4. For smokers who express a desire to use e-ciga-
rettes for cessation, health professionals should
ensure the smokers have access to, and are utiliz-
ing, behavioural support with the aim of achieving
complete smoking cessation and subsequent cessa-
tion of e-cigarette use as promptly as possible. It
should be clearly communicated that no product
can be recommended, and nor can an assurance
be provided as to either effectiveness or safety.
5. As e-cigarettes have been demonstrated to cause
adverse lung effects and their safety for long-term
use is unknown, they should not be used by non-
smokers or for extended periods by ex-smokers. E-
cigarettes, whether containing nicotine or not, are
not suitable consumer products.
6. Australia and New Zealand must take every action
to prevent burgeoning use of e-cigarettes in young
people as has occurred in other countries. The sale
or supply of e-cigarettes, e-liquids and devices to
people under the age of 18 years should not be
permitted and active surveillance is required by
bodies responsible for enforcing this.
7. Flavours in e-liquids are attractive to young people
and never smokers. Bans on flavourings should be
actively considered by governments.
8. As Australia and New Zealand both have well-
established processes to manage products making
a therapeutic claim, we recommend that any prod-
uct about which a therapeutic claim regarding
smoking cessation is made be managed through
these processes.
9. Noting existing regulations in Australia and New
Zealand, there is a clear need for the development
of a more comprehensive regulatory framework for
both e-cigarette devices and e-liquids.
10. Further high-quality research is urgently required,
including regarding the potential risks and benefits
of e-cigarette use in groups with higher rates of
smoking and those with special health needs.
CONCLUDING REMARKS
Australia and New Zealand must remain focused on
proven effective population tobacco control strategies
to reduce prevalence rates. We must also ensure
smokers have access to behavioural support and,
where required, therapeutic products which have been
through stringent regulatory approval processes.
TSANZ reconfirms its commitment to Article 5.3 of
the World Health Organization (WHO) Framework
Convention on Tobacco Control: ‘In setting and
implementing their public health policies with respect to
tobacco control, parties shall act to protect these policies
from commercial and other vested interests of the
tobacco industry in accordance with national law’.
Abbreviations: CSIRO, Commonwealth Scientific and Industrial
Research Organisation; EC, e-cigarette; ENDS, electronic
nicotine delivery system; NASEM, National Academies of
Sciences, Engineering and Medicine; TSANZ, Thoracic Society
of Australia and New Zealand
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